| HOME >> MEDICINE >> TECHNOLOGY |
8,185,240and $421,079 at September 30, 2010 and June 30, 2010, respectivelyInventory
5,218,254
3,588,824Advance payments
389,220
382,980Loans receivable
299,400
294,600Other current assets
172,189
77,283Total current assets42,140,14339,537,993Property and equipment, net17,023,43314,968,822Intangibles, net15,297,91115,232,286Total assets$74,461,487
$69,739,101Liabilities Current liabilities:Accounts payable and accrued expenses
$ 1,523,622
$ 1,715,781Accounts payable – construction related
1,131,717
2,248,849Short-term bank loans
1,497,000
1,473,000VAT taxes payable
583,630
658,312Income taxes payable
916,459
861,614Other taxes payable
59,801
19,564Dividends payable
54,857
72,995Other current liabilities
597,665
429,135Total current liabilities6,364,7517,479,250Total liabilities6,364,7517,479,250EquityStockholders' equity:Common stock, $0.001 par value, 50,000,000 shares authorized,
27,986
27,37227,986,026 and 27,371,526 shares issued and outstanding atSeptember 30, 2010 and June 30, 2010, respectivelySeries A convertible preferred stock, $0.001 par value 1,360,250 shares
1,360
1,360issued and outstanding at September 30, 2010 and June 30, 2010,RespectivelyAdditional paid-in capital
30,891,906
29,623,350Statutory reserve
3,732,883
3,732,883Treasury stock
(111,587)
(111,587)Retained earnings
29,310,447
25,687,770Accumulated other comprehensive income
3,797,958
2,845,076Total stockholders' equity67,650,95361,806,224Noncontrolling interest445,783453,627Total equity68,096,73662,259,851Tot
'/>"/>
| SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2010 PR Newswire. All rights reserved |